Targets › LGR5
1 program from 1 company in 5 trials: 4 Phase 3, 1 Phase 1; Oncology; next expected readout Jan 2028.
Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. (UniProt, O75473)
Open in Phaseline: the race on LGR5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Genmab | Petosemtamab (MCLA-158) bispecific antibody targeting EGFR and LGR5 | EGFR, CEACAM5, LGR5 | Phase 3 | Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid Tumors | Jan 2028 |
Head and Neck Squamous Cell Carcinoma (2) Colorectal Cancer (1) Left-sided Colorectal Cancer (1) Advanced/Metastatic Solid Tumors (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.